Eton Pharmaceuticals, Inc. (ETON)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$19.7M
Cash & Equivalents
$7.4M
Quarterly Burn Rate
$1,003M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (6 Assets)

DrugPhaseIndications
DESMOPRESSIN ACETATE
DESMODA 		APPROVED —
ZINC ACETATE
GALZIN 		APPROVED —
NITISINONE
NITISINONE 		APPROVED —
BETAINE
BETAINE 		APPROVED —
PROPRANOLOL HYDROCHLORIDE
HEMANGEOL 		APPROVED —
HYDROCORTISONE
ALKINDI SPRINKLE 		NDA —

Upcoming Catalysts

DateEventDrug
2026-08-23 Phase2 Readout —

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT07084818 Enabling Self-Care for Pessary Users in Rural Setting OTHER Enrolling By Invitation 120
NCT05262400 A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Brea... PHASE2 Active Not Recruiting 192

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ETON.

SEC EDGAR Filings

All SEC filings for Eton Pharmaceuticals, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.